Physician profile
Ripple Sharma
NPI 1205003167
$4,936.18
in general payments reported to CMS, 2019-2025
27 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $164 · 2021: $482 · 2022: $781 · 2023: $1,326 · 2024: $910 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,296 · Education: $38.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.72 |
| Education | $38.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,534.05 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $761.44 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $552.07 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $502.74 | 2019-2025 | |
| Pfizer INC. | $257.22 | 2019-2025 | |
| Braintree Laboratories, INC. | $153.46 | 2020-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $146.15 | 2019-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $144.87 | 2022-2023 | |
| Celgene Corporation | $128.27 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.37 | 2024-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $89.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $88.52 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $68.36 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $62.69 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $51.58 | 2023-2024 | Ocaliva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $49.58 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $44.83 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $32.86 | 2024 | Bylvay |
| Celltrion USA INC. | $28.14 | 2023 | Yuflyma |
| Novo Nordisk INC | $26.80 | 2025 | Wegovy |
| Alfasigma USA, INC. | $25.91 | 2020 | |
| Qol Medical, LLC | $24.20 | 2024 | Sucraid |
| Boston Scientific Corporation | $17.69 | 2023 | |
| Genzyme Corporation | $15.67 | 2023 | |
| Shionogi INC | $13.61 | 2019 | |
| Allergan, INC. | $12.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ripple Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.